Dry Eye

Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.

According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for both staining end points at day 15.

Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.

Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders about what she would like to see develop as both a researcher and a clinician in the dry eye space.

The drop has the potential to become the first-ever ocular surface indication for an IG.

Can a drop of perfluorohexyloctane, known to persist in the tear film, influence the precision of keratometry and ultimately affect surgical planning?

When her friend began experiencing dry eye symptoms while undergoing chemotherapy, Katherine Mastrota, OD, MS, FAAO, Dipl ABO, found herself in a unique position to provide specialized advice.

New data for 0.25% reproxalap was announced by Aldeyra Therapeutics, supporting the company’s NDA resubmission for the treatment of dry eye disease.

Participants received either Systane Hydration UD (Alcon, Fort Worth, TX) or saline eye drops (NeilMed, Santa Rosa, CA) 4 times a day for 4 weeks each.

Inflammation is both a cause and consequence of dry eye disease.

Deborah Ristvedt, DO, and Melissa Tawa, OD, FAAO, detail the benefits of interventional glaucoma during their CRU 2025 presentation.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Cecelia Koetting, OD, FAAO, DipABO, and Madeline Yung, MD, detailed the prevalence of the conditions, diagnostic tools, and treatment options.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment.

Healing properties can accelerate and improve outcomes for patients.

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief and targets all 3 layers of the tear film.

An overview of prescription medications available for DED.

Patients reported that Miebo significantly reduced overall symptoms severity at the primary endpoint of change from baseline in the severity of overall dry eye symptoms at day 7.

VEVYE Access for All aims to reduce barriers to dry eye disease therapy via a partnership with PhilRx.

The report found that 68% of employees experience digital eye strain symptoms such as blurred vision, eye strain, and dry, itchy eyes, with 59% reporting affects to productivity.

Persistent ocular surface dysfunction after cataract surgery impacts patient satisfaction despite 20/20 vision, with pre-op screening and tailored care being key components.

Milton Hom, OD, FAAO, took a deep dive into the lipid, aqueous, and mucin tear film layers to determine specialized treatment options for different types of dry eye.